TY - JOUR
T1 - A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Once-A-Day Tadalafil in Men with Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors
AU - Montorsi, Francesco
AU - Aversa, Antonio
AU - Moncada, Ignacio
AU - Perimenis, Petros
AU - Porst, Hartmut
AU - Barker, Clare
AU - Shane, Michael A.
AU - Sorsaburu, Sebastian
PY - 2011/9
Y1 - 2011/9
N2 - Introduction. The majority of subjects included in previous tadalafil once-a-day clinical trials were non-naïve to previous phosphodiesterase 5 (PDE5) inhibitors on demand. A study on PDE5 inhibitor naïve subjects was therefore warranted. Aim. To evaluate the efficacy and safety of once-a-day tadalafil in PDE5 inhibitor-naïve men with erectile dysfunction (ED). Main Outcomes Measures. Primary efficacy end points were changes from baseline to end point in the International Index of Erectile Function (IIEF) Erectile Function (EF) domain score and the per-subject proportion of "yes" responses to sexual encounter profile (SEP) question 2 (SEP2) and question 3 (SEP3). Methods. PDE5 inhibitor-naïve men with ED (N=217) were randomized in a 1:2 ratio to receive placebo or tadalafil 5mg once a day for 12 weeks. Enrollment began in January 2009 and the last subject completed in January 2010. Results. At end point, least square mean change from baseline IIEF-EF domain score (7.3 vs. 3.4), SEP2 (23.8% vs. 12.2%) and SEP3 (39.5% vs. 21.5%), was significantly larger for tadalafil vs. placebo (all P
AB - Introduction. The majority of subjects included in previous tadalafil once-a-day clinical trials were non-naïve to previous phosphodiesterase 5 (PDE5) inhibitors on demand. A study on PDE5 inhibitor naïve subjects was therefore warranted. Aim. To evaluate the efficacy and safety of once-a-day tadalafil in PDE5 inhibitor-naïve men with erectile dysfunction (ED). Main Outcomes Measures. Primary efficacy end points were changes from baseline to end point in the International Index of Erectile Function (IIEF) Erectile Function (EF) domain score and the per-subject proportion of "yes" responses to sexual encounter profile (SEP) question 2 (SEP2) and question 3 (SEP3). Methods. PDE5 inhibitor-naïve men with ED (N=217) were randomized in a 1:2 ratio to receive placebo or tadalafil 5mg once a day for 12 weeks. Enrollment began in January 2009 and the last subject completed in January 2010. Results. At end point, least square mean change from baseline IIEF-EF domain score (7.3 vs. 3.4), SEP2 (23.8% vs. 12.2%) and SEP3 (39.5% vs. 21.5%), was significantly larger for tadalafil vs. placebo (all P
KW - Erectile Dysfunction
KW - Phosphodiesterase Type 5 Inhibitors
KW - Tadalafil
UR - http://www.scopus.com/inward/record.url?scp=80052503312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052503312&partnerID=8YFLogxK
U2 - 10.1111/j.1743-6109.2011.02353.x
DO - 10.1111/j.1743-6109.2011.02353.x
M3 - Article
C2 - 21707928
AN - SCOPUS:80052503312
VL - 8
SP - 2617
EP - 2624
JO - Journal of Sexual Medicine
JF - Journal of Sexual Medicine
SN - 1743-6095
IS - 9
ER -